Everest Medicines Ltd
HKEX:1952
Everest Medicines Ltd
Cash from Financing Activities
Everest Medicines Ltd
Cash from Financing Activities Peer Comparison
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
E
|
Everest Medicines Ltd
HKEX:1952
|
Cash from Financing Activities
¥10.1m
|
CAGR 3-Years
-88%
|
CAGR 5-Years
-53%
|
CAGR 10-Years
N/A
|
Beigene Ltd
HKEX:6160
|
Cash from Financing Activities
-¥448.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Innovent Biologics Inc
HKEX:1801
|
Cash from Financing Activities
¥2.9B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
N/A
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Cash from Financing Activities
-¥893.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-98%
|
CAGR 10-Years
N/A
|
|
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Cash from Financing Activities
-¥2.4B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-39%
|
|
Imeik Technology Development Co Ltd
SZSE:300896
|
Cash from Financing Activities
-¥374.2m
|
CAGR 3-Years
-104%
|
CAGR 5-Years
-98%
|
CAGR 10-Years
N/A
|
See Also
What is Everest Medicines Ltd's Cash from Financing Activities?
Cash from Financing Activities
10.1m
CNY
Based on the financial report for Dec 31, 2023, Everest Medicines Ltd's Cash from Financing Activities amounts to 10.1m CNY.
What is Everest Medicines Ltd's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
-53%
The average annual Cash from Financing Activities growth rates for Everest Medicines Ltd have been -88% over the past three years , -53% over the past five years .